Free Newsletter
VC: Novexel gains $64.8M in second round
Free newsletter via e-mail
Tools
Novexel gains $64.8M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Novexel
|
$64.8M
|
Edmond de Rothschild Investment Partnersd |
Novexel is advancing four anti-infectives in its pipeline. |
|
Movetis
|
$63.5M
|
Sofinnova Partners/Life Sciences Partners |
Movetis will use the funds to complete development and filing of its lead phase III compound, continue clinical development of three other products and move four additional products into pre-clinical and phase I clinical development. |
|
Fluidigm
|
$37M
|
Wasatch Advisors |
Fluidigm will use the capital to boost sales and marketing of its BioMark system and TOPAZ system for protein crystallization and to develop new products in the pipeline. |
|
Variation Biotechnologies
|
$35.7M
|
Clarus Ventures |
The money goes to advance the company's Variosite vaccine platform into clinical development, beginning with lead vaccine candidates for influenza. |
|
Proprius Pharmaceuticals
|
$11M - $17M
|
Atlas Venture |
Much of that will go to develop Indaflex, a topical non-steroidal anti-inflammatory drug formulation in Phase II clinical development for osteoarthritis of the knee. |
|
Gentiae Clinical Research
|
$16M
|
Bay City Capital |
Gentiae provides comprehensive cardiac assessment services for clinical trials. |
|
Juvaris BioTherapeutics
|
$6M
|
Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund |
The funds will enable Juvaris to advance its lead vaccine products for influenza and pneumonia indications to clinical trials. The company will also pursue immunotherapy products for Hepatitis B and Biodefense applications. |
|
F-Star
|
$1.94M
|
Atlas Venture |
The money goes to optimize its modular antibody technology, to advancing initiatives to partner its research and development platform, and to commencing the development of a proprietary product pipeline. |
